Corrigendum to: CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.

Griesel, Rulan; Maartens, Gary; Chirehwa, Maxwell; Sokhela, Simiso; Akpomiemie, Godspower; Moorhouse, Michelle; Venter, Francois; Sinxadi, Phumla.

Afiliação

Griesel R; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Maartens G; Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Chirehwa M; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Sokhela S; Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Akpomiemie G; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Moorhouse M; Ezintsha, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Venter F; Ezintsha, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Sinxadi P; Ezintsha, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Clin Infect Dis ; 74(4): 755, 2022 Mar 01.

Article em En | MEDLINE | ID: mdl-35099526

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article